Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Evaluation of Fractionated Radio-Immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-Cell Lymphoma.

Next Previous
Trial Profile

Phase II Study of Evaluation of Fractionated Radio-Immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-Cell Lymphoma.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epratuzumab Y-90 (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ALYSA

    • Most Recent Events

    • 10 Jun 2013 Updated interim results presented at Society of Nuclear Medicine and Molecular Imaging 2013 Annual Meeting, according to an Immunomedics media release.
    • 11 Dec 2012 Updated results were presented at the 2012 Annual Meeting of American Society of Hematology (ASH), according to an Immunomedics media release.
    • 05 Nov 2012 Results have been presented at the 54th American Society of Hematology (ASH) Annual Meeting according to an Immunomedics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top